- Home
- NITO vs QNRX Comparison
NITO vs QNRX Comparison
Compare NITO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- QNRX
- Stock Information
- Founded
- NITO 2009
- QNRX 2018
- Country
- NITO Israel
- QNRX United States
- Employees
- NITO N/A
- QNRX N/A
- Industry
- NITO
- QNRX Medical/Dental Instruments
- Sector
- NITO
- QNRX Health Care
- Exchange
- NITO NYSE
- QNRX Nasdaq
- Market Cap
- NITO 4.2M
- QNRX 3.3M
- IPO Year
- NITO N/A
- QNRX N/A
- Fundamental
- Price
- NITO $0.30
- QNRX $8.82
- Analyst Decision
- NITO
- QNRX
- Analyst Count
- NITO 0
- QNRX 0
- Target Price
- NITO N/A
- QNRX N/A
- AVG Volume (30 Days)
- NITO 5.6M
- QNRX 522.9K
- Earning Date
- NITO 05-15-2025
- QNRX 05-13-2025
- Dividend Yield
- NITO N/A
- QNRX N/A
- EPS Growth
- NITO N/A
- QNRX N/A
- EPS
- NITO N/A
- QNRX N/A
- Revenue
- NITO $232,000.00
- QNRX N/A
- Revenue This Year
- NITO N/A
- QNRX N/A
- Revenue Next Year
- NITO N/A
- QNRX N/A
- P/E Ratio
- NITO N/A
- QNRX N/A
- Revenue Growth
- NITO 24.74
- QNRX N/A
- 52 Week Low
- NITO $0.16
- QNRX $5.01
- 52 Week High
- NITO $3.49
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- NITO 49.96
- QNRX 57.93
- Support Level
- NITO $0.25
- QNRX $8.67
- Resistance Level
- NITO $0.30
- QNRX $9.30
- Average True Range (ATR)
- NITO 0.03
- QNRX 0.62
- MACD
- NITO -0.00
- QNRX 0.03
- Stochastic Oscillator
- NITO 67.66
- QNRX 56.63
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.